- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06858111
Fertilo In Vitro Research Study and Trial (FIRST)
Fase III Estudo de Controle randomizado para investigar a segurança e a eficácia do Fertilo versus Medicult in vitro Maturação (IVM)
The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation.
Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm.
- Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours.
- Arm 2 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Medicult IVM for 30 hours.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Clinical Trials
- Número de telefone: 512-535-1164
- E-mail: clinicaltrials@gametogen.com
Locais de estudo
-
-
California
-
Clovis, California, Estados Unidos, 93611
- Recrutamento
- Women's Specialty & Fertility Center
-
Contato:
- Casey Study Coordinator
- Número de telefone: 559-299-7700
- E-mail: cstorm@santehealth.net
-
Investigador principal:
- Howard Synn, MD
-
Encino, California, Estados Unidos, 91436
- Recrutamento
- HRC Fertility
-
Investigador principal:
- Robert Boostanfar, MD
-
Contato:
- Shanise Ashiem
- Número de telefone: 818-788-7288
- E-mail: clinicaltrialsENC@havingbabies.com
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33759
- Recrutamento
- Florida Fertility Institute
-
Contato:
- Gayle Cameron
- Número de telefone: 727-724-9730
- E-mail: gaylec@xxresearch.com
-
Investigador principal:
- Mark Sanchez, MD
-
Pembroke Pines, Florida, Estados Unidos, 33026
- Recrutamento
- IVF Florida
-
Contato:
- Karina Stroker
- Número de telefone: 62518 954-247-6200
- E-mail: karina.stroker@usfertility.com
-
Investigador principal:
- Luis Hoyos, MD
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Recrutamento
- Shady Grove Fertility
-
Investigador principal:
- Kate Devine, MD
-
Contato:
- Joshua McKeeby
- Número de telefone: 301-545-1423
- E-mail: sgfclinicalresearchteam@sgfertility.com
-
-
New York
-
New York, New York, Estados Unidos, 10019
- Recrutamento
- Columbia University Fertility Center
-
Contato:
- Stephanie Morgan
- Número de telefone: 212-314-8837
- E-mail: sm3415@cumc.columbia.edu
-
Investigador principal:
- Eric Forman, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- Recrutamento
- Reach Fertility
-
Contato:
- Stephanie Graham, MS
- Número de telefone: 704-343-4455
- E-mail: Stephanie.Graham@northcarolinafertility.com
-
Investigador principal:
- Jack Crain, MD
-
Raleigh, North Carolina, Estados Unidos, 27607
- Recrutamento
- Conceptions Fertility
-
Investigador principal:
- John Park, MD
-
Contato:
- Sofia Sequeira
- Número de telefone: 919-782-5911
- E-mail: ccresearch@carolinaconceptions.com
-
-
Texas
-
Addison, Texas, Estados Unidos, 75001
- Recrutamento
- Aspire Fertility Dallas
-
Investigador principal:
- Christine Mansfield, MD
-
Contato:
- Alexis Denson
- Número de telefone: 214-414-3806
- E-mail: Research@inceptionllc.com
-
Austin, Texas, Estados Unidos, 78705
- Recrutamento
- Aspire Fertility Austin
-
Investigador principal:
- Angela Kelley, MD
-
Contato:
- Laurel Schultz
- Número de telefone: 512-479-7979
- E-mail: Research@inceptionllc.com
-
Bedford, Texas, Estados Unidos, 76022
- Recrutamento
- Care Fertility
-
Investigador principal:
- Kevin Doody, MD
-
Contato:
- Michelle Evans
- Número de telefone: 1033 817-540-7070
- E-mail: michellee@embryo.net
-
Contato:
- Charlene Nwajei
- E-mail: charlenen@embryo.net
-
Dallas, Texas, Estados Unidos, 75231
- Recrutamento
- Dallas Fort Worth Fertility Associates
-
Contato:
- Jenny Patel
- Número de telefone: 214-363-5965
- E-mail: thirdparty@dallasfertility.com
-
Investigador principal:
- Samuel Chantilis, MD
-
San Antonio, Texas, Estados Unidos, 78528
- Recrutamento
- Aspire Fertility San Antonio
-
Investigador principal:
- Jennifer Knudtson, MD
-
Contato:
- Laurel Anderson
- Número de telefone: 210-337-8453
- E-mail: Research@inceptionllc.com
-
San Antonio, Texas, Estados Unidos, 78249
- Recrutamento
- Pozitivf Fertility San Antonio
-
Contato:
- Jose Acevedo
- Número de telefone: 3046 210-404-2229
- E-mail: jose.acevedo@pozitivf.com
-
Investigador principal:
- Francisco Arredondo, MD
-
Webster, Texas, Estados Unidos, 77598
- Recrutamento
- Shady Grove Houston
-
Contato:
- Cara Barrier, RN
- Número de telefone: 832-342-9129
- E-mail: cara.barrier@sgfertility.com
-
Contato:
- Maryanne Fisher, RN
- Número de telefone: 281-557-3084
- E-mail: maryanne.fisher@sgfertility.com
-
Investigador principal:
- Vicki Schnell, MD
-
-
Utah
-
Pleasant Grove, Utah, Estados Unidos, 84062
- Recrutamento
- Utah Fertility Center
-
Contato:
- Coral Halterman, RN
- Número de telefone: 7036 801-785-5100
- E-mail: coral.halterman@utahfertility.com
-
Investigador principal:
- Shawn Gurtcheff, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Written informed consent.
- Premenopausal, Age 18-35.
- Body mass index (BMI) 21-40.
- Candidate for IVF according to the ASRM definition (infertile for ≥12 months, require the use of donor sperm, or the inability to achieve a successful pregnancy based on a patient's medical, sexual, and reproductive history, age, physical findings, diagnostic testing, or any combination of those factors).
- No contraindications to the use of oral contraceptive pills (OCP) or gonadotropins.
- Plan to use embryos for transfer within 2 months of blastocyst cryopreservation.
- Anti-mullerian hormone (AMH) ≥ 3 ng/mL within 6 months of Screening/Visit 1 or assessed at the screening visit.
- Normal uterine cavity as assessed by hysteroscopy, hysterosalpingography or sonohysterography within 12 months of Screening/Visit 1 or assessed at the screening visit.
- Having adequate visualization of both ovaries, without evidence of significant abnormality/pathology or major cyst documented by transvaginal ultrasound within 3 months of screening or assessed during screening period.
- No endometriosis of American Fertility Society (AFS) grade 3 or 4 or presence of endometrioma.
- Minimum of 1 month without treatment with either clomiphene citrate, GnRH agonist or gonadotropins prior to start of ovarian stimulation.
- Have a male partner with semen analysis within the past 12 months prior to randomization considered adequate to proceed with intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If this criterion is not met, the subject can only be entered if donor sperm will be used.
Exclusion Criteria:
- History of recurrent pregnancy loss (defined as >2 clinical pregnancies without live birth).
- Baseline prolactin levels greater than 30 ng/ml
- Male: requirement for retrograde ejaculation procedures or surgical sperm retrievals.
- Any clinically relevant pathology that in the judgment of the investigator could impair embryo implantation or pregnancy continuation.
- Use of preimplantation genetic testing (PGT) of oocytes, embryos, or transferred blastocysts during participation in the study.
- Use of donated oocytes, embryos or blastocysts for this treatment cycle while participating in the study or use of oocytes, embryos, or blastocysts from a previous treatment cycle.
- Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Fertilo
Immature cumulus-oocyte complexes (COCs) are oocytes surrounded by cumulus cells that have not yet matured. The COCs are cultured in Fertilo coculture condition then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose. |
Fertilo is an engineered line of ovarian support cells that aid egg maturation. |
|
Comparador Ativo: Medicult IVM®
Immature COCs are cultured in the standard IVM system MediCult IVM® then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose. |
MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures.
Prazo: 12 weeks gestation
|
Cumulative ongoing pregnancy from cycles initiated within 6 months post-randomization. The primary endpoint of ongoing pregnancy is assessed at 12 weeks gestation or later. Cumulative ongoing pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with a detectable fetal heartbeat, considered normal and healthy, are considered as having achieved an ongoing pregnancy. "Normal" will be determined as expected for the gestational age ranging from 110 bpm to 180 bpm and measured via ultrasound. Ongoing pregnancy is recorded as either a Yes or No for normal fetal heart rate present for each of the Subject's transfer cycles. Subjects without an ongoing pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., a live birth). Cumulative ongoing pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves an ongoing pregnancy, or a No otherwise. |
12 weeks gestation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Metaphase II (MII) Formation
Prazo: 30 hours post-oocyte retrieval
|
MII formation rate is assessed at 30 hours post-oocyte retrieval. A Metaphase II (MII) oocyte is defined as an oocyte with a first polar body (PB1). The MII formation rate is measured as a Subject's total number of MII oocytes divided by their total number of COCs. The MII formation rate is multiplied by 100 and expressed as a percentage. |
30 hours post-oocyte retrieval
|
|
Fertilization Rate
Prazo: 16-18 hours post-ICSI
|
Fertilization rate is assessed at 16-18 hours post-ICSI. Fertilized embryos displaying 2 pronuclei and 2 polar bodies are considered normally fertilized. Fertilized embryos with no pronuclei are considered not fertilized. Fertilized embryos with one pronuclei are held to determine cleavage, as pronuclei visualization timing may mask the second pronucleus. The fertilization rate is measured as a Subject's total number of fertilized embryos divided by their total number of COCs. The fertilization rate is multiplied by 100 and expressed as a percentage. |
16-18 hours post-ICSI
|
|
Embryo cleavage rate
Prazo: Day 3 post-ICSI
|
Embryo cleavage rate is assessed at day 3 post-ICSI. Embryos with 2 or more cells are considered as cleaved. Fertilized embryos displaying a single cell will be considered not cleaved. The cell cleavage rate is measured as a Subject's total number of embryos considered as cleaved divided by their total number of COCs. The cell cleavage rate is multiplied by 100 and expressed as a percentage. |
Day 3 post-ICSI
|
|
High quality blastocyst formation rate.
Prazo: Day 5, 6, and 7 post-ICSI
|
High quality blastocyst formation rate is assessed at day 5, 6 and 7 post-ICSI. Embryos that have successfully passed the morula stage, as indicated by cavitation, will be designated as blastocysts and will be graded according to the Gardner Scale. Blastocysts having a Gardner Scale score of 3CC or higher are considered as high quality blastocysts. The high quality blastocyst formation rate is measured as a Subject's total number of high quality blastocysts divided by their total number of COCs. The high quality blastocyst formation rate is multiplied by 100 and expressed as a percentage. |
Day 5, 6, and 7 post-ICSI
|
|
High quality vitrified blastocyst rate.
Prazo: Day 5, 6, and 7 post-ICSI
|
High quality vitrified blastocyst rate is assessed at day 5, 6 and 7 post-ICSI. Embryos deemed high quality, as measured by a Gardner score of 3CC of greater, that have been vitrified, a method of rapid cryopreservation for future embryo transfer, will be designated as high quality vitrified blastocysts. The high quality vitrified blastocyst rate is measured as a Subject's total number of high quality blastocysts that are vitrified divided by their total number of COCs. The high quality vitrified blastocyst rate is multiplied by 100 and expressed as a percentage. |
Day 5, 6, and 7 post-ICSI
|
|
Cumulative biochemical pregnancy.
Prazo: 10 to 14 days following FET
|
Cumulative biochemical pregnancy from cycles initiated within 6 months post randomization. Biochemical pregnancy is assessed at 10 to 14 days following FET. Cumulative biochemical pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with BHCG value greater than 5 mIU/mL on two separate tests are considered as achieving biochemical pregnancy. Biochemical pregnancy is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a biochemical pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., a clinical pregnancy, ongoing pregnancy, or live birth). Cumulative biochemical pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves a biochemical pregnancy, or a No otherwise. |
10 to 14 days following FET
|
|
Cumulative clinical pregnancy.
Prazo: 4-6 weeks gestation
|
Cumulative clinical pregnancy from cycles initiated within 6 months post randomization is assessed at 4-6 weeks gestation. Cumulative clinical pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with a gestational sac visualized with TVU are considered as having achieved a clinical pregnancy. Clinical pregnancy is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a clinical pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., an ongoing pregnancy or live birth). Cumulative clinical pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves a clinical pregnancy, or a No otherwise. |
4-6 weeks gestation
|
|
Cumulative live birth.
Prazo: Greater than 24 weeks gestation
|
Cumulative live birth from cycles initiated within 6 months post-randomization. Live birth is confirmed at >24 weeks gestation by the presence of signs of life such as breathing, heartbeat, pulsation of the umbilical cord, or definitive movement of voluntary muscles. Cumulative live birth is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with at least one neonate meeting the definition of live birth are considered as having achieved a live birth. Live birth is recorded as either a Yes or No for each of the Subject's transfer cycles. Subjects without a live birth assessment are considered as a No. Cumulative live birth is derived as either a Yes, if at least one of the first two embryo transfers achieves a live birth, or a No otherwise. |
Greater than 24 weeks gestation
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GAM-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Prazo de Compartilhamento de IPD
Beginning 3 months and ending 5 years following article publication.
Critérios de acesso de compartilhamento IPD
Researchers who provide a methodologically sound proposal. Requestord will need to contact clinicaltrials@gametogen.com and sign a data access agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .